All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome

Clinical and Experimental Dermatology

Volumn 34, Issue 2, 2009, Pages 264-266

  Ingram, J R ^a   Griffiths, A P ^b   Roberts, D L ^a  

^a SINGLETON HOSPITAL   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MUIR TORRE SYNDROME; PRIORITY JOURNAL; SEBACEOUS CARCINOMA;

ADENOCARCINOMA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FACIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUIR-TORRE SYNDROME; SEBACEOUS GLAND NEOPLASMS;

EID: 58549108190     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02830.x     Document Type: Letter

References (4)

1. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 1991 90 : 606 13.
2. Machin P, Catasus L, Pons C et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol 2002 29 : 415 20.
3. Mant D, Fowler G. Mass screening: theory and ethics. Br Med J 1990 300 : 916 18.
4. Ponti G, Losi L, Di Gregorio C et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas. Cancer 2005 103 : 1018 25.